Monitor for completion of technology transfer and receipt of the $600,000 upfront fee, which is the first concrete milestone. Watch for any sublicensing announcements by BioPhoenix, which would trigger the first-sublicense fee and ongoing revenue share. Track Ainos' progress in its Chemical Intelligence business as the deal reduces pharmaceutical development distractions.
Price Chart
Executive Summary
Ainos entered into a global exclusive license agreement with BioPhoenix Co., Ltd. for its VELDONA low-dose oral interferon alpha platform, covering Sjögren's Disease and Thrombocytopenia. Ainos receives a $600,000 upfront license fee, a one-time first-sublicense fee (undisclosed amount), and 25% of net sublicensing revenue, with a potential total licensing framework of approximately $10 million. The deal shifts clinical and regulatory funding to BioPhoenix, reducing Ainos' capital requirements and allowing it to focus on its Chemical Intelligence business.
Key Financial Metrics
Key Facts
- Ainos granted BioPhoenix an exclusive, worldwide, irrevocable, sublicensable license for VELDONA in Sjögren's Disease and Thrombocytopenia.
- Upfront license fee of $600,000, payable after technology transfer and data package delivery.
- Ainos retains 25% of net sublicensing revenue from BioPhoenix sublicenses.
- Total potential licensing framework of approximately $10 million, including upfront fee, additional indication licenses, and first-sublicense fee.
- BioPhoenix assumes funding and execution of assigned clinical and regulatory activities.
- Ainos retains ownership of the VELDONA platform and background IP.
- Agreement term continues until later of last-to-expire patent or 20 years from effective date.
- Ainos has a 10-year non-compete covenant for the licensed indications.
Financial Impact
$600,000 upfront license fee; potential total licensing framework of approximately $10 million; 25% of net sublicensing revenue.
Risk Factors
- Upfront fee is contingent on technology transfer completion and data package delivery.
- Additional indication licenses and sublicensing revenue are not guaranteed.
- Clinical and regulatory success of VELDONA depends on BioPhoenix's execution and funding.
- No assurance of future drug approval or commercial success.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044454 |
| Exhibit: ex99-1.htm | 0001493152-26-044454 |
| Document: form8-k.htm | 0001493152-26-044454 |
| Document: 0001493152-26-044454-index-headers.html | 0001493152-26-044454 |
| Document: 0001493152-26-044454-index.html | 0001493152-26-044454 |
| Document: 0001493152-26-044454.txt | 0001493152-26-044454 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $0.9315 | awaiting T+20 | — | $0.7830 (−15.94%) |
Sep 28, 2026 28d ago | 8-K | $1.33 $0.7825 | ▼ −41.17% | ▼ −41.13% | $0.7830 (−41.13%) |
Jul 24, 2026 13w ago | 424B5 | $1.40 $1.43 | ▼ −2.14% | ▲ +1.48% | $0.7830 (+44.07%) |
Jul 9, 2026 15w ago | 8-K | $1.89 $1.49 | ▼ −21.16% | ▼ −23.59% | $0.7830 (−58.57%) |
May 27, 2026 21w ago | Insider Cluster | $2.74 $1.73 | ▼ −36.86% | ▼ −33.72% | $0.7830 (−71.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers